Table 2.
Treatment-related adverse events
| Number of events (%) | ||||||
|---|---|---|---|---|---|---|
| DC vaccination (n = 27) | DC vaccination + cisplatin (n = 27) | p value | ||||
| Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 3 | ||
| Any event | 22 (81) | 2 (7) | 18 (67) | 7 (26) | 1 (4) | 0.159 |
| Injection site reaction | 20 (74) | 1 (4) | 10 (37) | 0 | 0 | 0.008 |
| Flu-like symptoms | 19 (70) | 3 (11) | 17 (63) | 0 | 0 | 0.092 |
| Nausea | 4 (15) | 0 | 15 (56) | 3 (11) | 0 | < 0.001 |
| Vomiting | 4 (15) | 0 | 1 (4) | 3 (11) | 0 | 0.091 |
| Creatinine increased | 2 (7) | 0 | 3 (11) | 0 | 0 | 0.639 |
| Constipation | 0 | 0 | 7 (26) | 0 | 0 | 0.005 |
| Fatigue | 0 | 0 | 4 (15) | 3 (11) | 0 | 0.018 |
| Tinnitus | 0 | 0 | 3 (11) | 2 (7) | 0 | 0.064 |
Adverse events that occurred in at least 10% of patients and were classified as possibly, probably or definitely related to the treatment by the investigator are depicted